Author: Jane Edwards|| Date Published: August 10, 2016
The International AIDS Vaccine Initiative has received a potential seven-year, $98 million contract from the National Institutes of Health to support the agency™s efforts to develop a vaccine against the disease.
IAVI will work with NIH™s National Institute of Allergy and Infectious Diseases to characterize and produce HIV envelope protein immunogens, IAVI said Tuesday.
NIAID-backed scientists designed such immunogens in order to develop vaccine candidates that work to generate immune response against HIV infection and facilitate the evaluation of such experimental vaccines in human clinical trials.
Mark Feinberg, IAVI president and CEO, said IAVI is pleased to provide product development services to NIAID in support of its AIDS vaccine development initiatives.
IAVI is a two-decade-old nonprofit organization that aims to advance AIDS vaccine research and development programs through collaboration with government agencies, pharmaceutical firms, hospitals and universities in 25 countries.
PDW is acquiring Vanteon to expand tactical communications capabilities The acquisition will bring expertise in RF systems, software-defined radios and…
CISA is planning a $100 million cyber operations contract supporting threat-hunting missions The requirement will provide technical and operational support…
Valiant Solutions is expanding its cybersecurity portfolio through the acquisition of BreakPoint Labs The acquisition will bring operational technology security,…
The International AIDS Vaccine Initiative has received a potential seven-year, $98 million contract from the National Institutes of Health to support the agency™s efforts to develop a vaccine against the disease.
